A case of therapy-related acute lymphoblastic leukemia with t(11;19)(q23;p13.3) and MLL/MLLT1 gene rearrangement. 2011

Byong-Joon Yoo, and Myung-Hyun Nam, and Hwa-Jung Sung, and Chae-Seung Lim, and Chang-Kyu Lee, and Yun-Jung Cho, and Kap-No Lee, and Soo-Young Yoon
Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea.

Therapy-related ALL (t-ALL) is a rare secondary leukemia that develops after chemotherapy and/or radiotherapy for primary malignancies. Chromosomal 11q23 abnormalities are the most common karyotypic alterations in t-ALL. The t(11;19)(q23;p13) aberration is extremely rare and has not been confirmed at the molecular genetic level. Here, we report a case of t-ALL with t(11;19)(q23;p13.3) and MLL-MLLT1 (alias ENL) gene rearrangement confirmed by cytogenetic analysis, multiplex reverse transcription-PCR (multiplex RT-PCR), and DNA sequencing in a patient who had undergone treatment for breast cancer. A 40-yr-old woman developed acute leukemia 15 months after undergoing 6 cycles of adjuvant chemotherapy (doxorubicin 60 mg/m² and cyclophosphamide 600 mg/m²), radiation therapy (dose, 5,900 cGy), and anticancer endocrine therapy with tamoxifen. The complete blood cell counts and bone marrow examination showed increased blasts and the blasts showed B lineage immunophenotype (positive for CD19, CD34, and cytoplasmic CD79a). Cytogenetic analysis revealed the karyotype 47,XX,+X,t(11;19)(q23;p13.3)[4]/46,XX[16]. FISH analyses, multiplex RT-PCR, and DNA sequencing confirmed the MLL-MLLT1 gene rearrangement. The patient underwent induction chemotherapy with fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD) and achieved complete remission. Subsequently, she underwent consolidation chemotherapy, but died of brain ischemia in the pons and the region of the middle cerebral artery. To our knowledge, this is the first case report of t-ALL with t(11;19)(q23;p13.3) and the MLL-MLLT1 gene rearrangement.

UI MeSH Term Description Entries
D007621 Karyotyping Mapping of the KARYOTYPE of a cell. Karyotype Analysis Methods,Analysis Method, Karyotype,Analysis Methods, Karyotype,Karyotype Analysis Method,Karyotypings,Method, Karyotype Analysis,Methods, Karyotype Analysis
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009687 Nuclear Proteins Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus. Nucleolar Protein,Nucleolar Proteins,Nuclear Protein,Protein, Nuclear,Protein, Nucleolar,Proteins, Nuclear,Proteins, Nucleolar
D011495 Histone-Lysine N-Methyltransferase An enzyme that catalyzes the methylation of the epsilon-amino group of lysine residues in proteins to yield epsilon mono-, di-, and trimethyllysine. Protein Lysine Methyltransferase,Protein Methylase III,Protein Methyltransferase III,Histone-Lysine Methyltransferase,Histone Lysine Methyltransferase,Histone Lysine N Methyltransferase,Methyltransferase, Histone-Lysine,Methyltransferase, Protein Lysine,N-Methyltransferase, Histone-Lysine
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002880 Chromosomes, Human, Pair 11 A specific pair of GROUP C CHROMOSOMES of the human chromosome classification. Chromosome 11
D002888 Chromosomes, Human, Pair 19 A specific pair of GROUP F CHROMOSOMES of the human chromosome classification. Chromosome 19
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271

Related Publications

Byong-Joon Yoo, and Myung-Hyun Nam, and Hwa-Jung Sung, and Chae-Seung Lim, and Chang-Kyu Lee, and Yun-Jung Cho, and Kap-No Lee, and Soo-Young Yoon
June 2010, American journal of hematology,
Byong-Joon Yoo, and Myung-Hyun Nam, and Hwa-Jung Sung, and Chae-Seung Lim, and Chang-Kyu Lee, and Yun-Jung Cho, and Kap-No Lee, and Soo-Young Yoon
December 1999, Leukemia,
Byong-Joon Yoo, and Myung-Hyun Nam, and Hwa-Jung Sung, and Chae-Seung Lim, and Chang-Kyu Lee, and Yun-Jung Cho, and Kap-No Lee, and Soo-Young Yoon
January 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Byong-Joon Yoo, and Myung-Hyun Nam, and Hwa-Jung Sung, and Chae-Seung Lim, and Chang-Kyu Lee, and Yun-Jung Cho, and Kap-No Lee, and Soo-Young Yoon
March 2007, Leukemia,
Byong-Joon Yoo, and Myung-Hyun Nam, and Hwa-Jung Sung, and Chae-Seung Lim, and Chang-Kyu Lee, and Yun-Jung Cho, and Kap-No Lee, and Soo-Young Yoon
July 2015, Cureus,
Byong-Joon Yoo, and Myung-Hyun Nam, and Hwa-Jung Sung, and Chae-Seung Lim, and Chang-Kyu Lee, and Yun-Jung Cho, and Kap-No Lee, and Soo-Young Yoon
July 2016, Leukemia,
Byong-Joon Yoo, and Myung-Hyun Nam, and Hwa-Jung Sung, and Chae-Seung Lim, and Chang-Kyu Lee, and Yun-Jung Cho, and Kap-No Lee, and Soo-Young Yoon
February 2010, Cancer genetics and cytogenetics,
Byong-Joon Yoo, and Myung-Hyun Nam, and Hwa-Jung Sung, and Chae-Seung Lim, and Chang-Kyu Lee, and Yun-Jung Cho, and Kap-No Lee, and Soo-Young Yoon
July 1997, American journal of hematology,
Byong-Joon Yoo, and Myung-Hyun Nam, and Hwa-Jung Sung, and Chae-Seung Lim, and Chang-Kyu Lee, and Yun-Jung Cho, and Kap-No Lee, and Soo-Young Yoon
May 1999, Leukemia,
Byong-Joon Yoo, and Myung-Hyun Nam, and Hwa-Jung Sung, and Chae-Seung Lim, and Chang-Kyu Lee, and Yun-Jung Cho, and Kap-No Lee, and Soo-Young Yoon
June 2011, British journal of haematology,
Copied contents to your clipboard!